

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**VERQUVO**  
(vericiguat)

**Status: CVS Caremark Criteria**

**Type: Initial Prior Authorization**

## POLICY

### FDA-APPROVED INDICATIONS

Verquvo is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed to reduce the risk of cardiovascular death and heart failure hospitalization in an adult patient with symptomatic chronic heart failure

**AND**

- The patient has a left ventricular ejection fraction (LVEF) less than 45 percent. Documentation is required for approval.

**AND**

- The patient is currently receiving optimal therapy for heart failure management (e.g., angiotensin-converting enzyme inhibitor [ACEI], angiotensin II receptor blocker [ARB], angiotensin receptor-neprilysin inhibitor [ARNI], beta-blocker)

**AND**

- If the request is not for continuation of therapy, the patient has had any of the following: A) Hospitalization for heart failure within the past 6 months, B) Use of outpatient intravenous (IV) diuretics for heart failure within the past 3 months

### REFERENCES

1. Verquvo [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; January 2021.
2. Lexicomp Online, Lexi-Drugs Online Hudson, Ohio: UpToDate, Inc.; 2021; Accessed March 12, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed March 15, 2021.
4. Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. Published online January 2021. Available at: [https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022?\\_ga=2.266943758.1073019511.1611765807-2024013049.1611765807](https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022?_ga=2.266943758.1073019511.1611765807-2024013049.1611765807)